If the pair finds potential treatments in the discovery deal, they will ink a new collaboration to advance them.

Beacon Capital's incubator will offer up to $50 million in seed funding, as well as office and lab space.

The biotech unveiled plans to sell 9 million shares hours before Kerrisdale Capital’s attack and abandoned them hours after it hit.

The funds will carry TCR2 into 2021, allowing it to bring its lead asset through clinical proof of concept.

The decision, which Alder described as mutual, leaves the biotech without a permanent leader in the runup to filing for approval of its migraine drug.

Prothena is getting $150 million up front for work on a trio of proteins implicated in neuro diseases.

Eye disease specialist Ocugen remains on course to have two drugs in late-stage testing before the end of the year as its dry eye disease candidate OCU310…

The VC fund is setting up the venture with its CSO, David Grainger, Ph.D., and Johnson & Johnson’s Richard Mason. 

The new funding will propel Unity Biotechnologies' osteoarthritis asset into its first clinical trial.

The short seller launched the assault after seeing shares in Proteostasis rise 200% in three months.